Hydroxyurea, also called hydroxycarbamide, is an oral medicine that inhibits DNA synthesis. It is used as a disease-modifying treatment for sickle cell disease and as a cytoreductive treatment—a treatment that reduces blood-cell production—in certain blood disorders and cancers. Its clinical effects depend on the condition being treated: suppression of cell proliferation is central to its use in hematologic disorders, whereas increased fetal hemoglobin production is an important part of its benefit in sickle cell disease.
Chemical and pharmacological properties
Hydroxyurea is a small molecule with the molecular formula . It is a hydroxylated derivative of urea and is classified as an antimetabolite, a substance that interferes with processes needed for cell growth and replication. In oncology, it is considered a form of chemotherapy.
Following oral administration, hydroxyurea is readily absorbed. Renal elimination contributes substantially to its clearance, so impaired kidney function can increase exposure to the drug. Available formulations, approved indications, and age limits differ among countries and products.
Mechanism of action
Inhibition of DNA synthesis
Hydroxyurea inhibits ribonucleotide reductase, the enzyme that converts ribonucleotides into deoxyribonucleotides, the building blocks required for DNA synthesis. It interferes with the enzyme’s radical-dependent activity, reducing the supply of these building blocks.
The resulting effect is most pronounced during the DNA-synthesis phase of the cell cycle. Rapidly dividing cells, including blood-forming cells in the bone marrow, are particularly susceptible. This explains both its capacity to lower excessive blood-cell counts and its principal dose-limiting toxicity: suppression of normal blood-cell production.
Effects in sickle cell disease
In sickle cell disease, hydroxyurea increases the proportion of fetal hemoglobin, usually abbreviated HbF. Fetal hemoglobin interferes with the polymerization of sickle hemoglobin when oxygen levels fall, reducing the tendency of red blood cells to become rigid and sickle-shaped.
Its benefits are not explained by fetal hemoglobin alone. Hydroxyurea also lowers white-cell and reticulocyte counts and alters cellular interactions involved in small-vessel obstruction. The pathways responsible for its stimulation of fetal hemoglobin are complex and not completely resolved.
Clinical uses
Sickle cell disease
Hydroxyurea is an established disease-modifying treatment for sickle cell disease, with particularly strong evidence in sickle cell anemia. Randomized controlled trials in adults and children have demonstrated reductions in painful vaso-occlusive episodes and acute chest syndrome, a potentially serious pulmonary complication. Treatment can also reduce hospitalizations and the need for blood transfusions.
Its effects develop over time; it is not an immediate treatment for an acute pain episode. Responses vary between individuals, and benefits depend in part on sustained exposure. An increase in fetal hemoglobin and red-cell size commonly accompanies treatment, although neither measurement alone fully captures clinical benefit.
Hydroxyurea does not remove the inherited cause of sickle cell disease and is distinct from potentially curative approaches such as hematopoietic stem cell transplantation and certain forms of gene therapy.
Myeloproliferative neoplasms
Hydroxyurea is widely used to control elevated blood-cell counts in polycythemia vera and essential thrombocythemia. These are chronic disorders in which abnormal bone-marrow cells produce excessive numbers of blood cells.
In polycythemia vera, hydroxyurea can reduce red-cell production and help control other elevated blood counts. In essential thrombocythemia, it lowers platelet counts and is used in treatment strategies intended to reduce thrombosis risk in selected patients. It controls manifestations of these disorders rather than reliably eliminating the underlying abnormal cell population.
Leukemia and other cancers
Hydroxyurea can rapidly lower very high white-cell counts in some forms of leukemia. Its role is often temporary cytoreduction rather than definitive treatment. Its historical use in chronic myeloid leukemia has largely been superseded by targeted therapies.
Some product authorizations also include use with radiation therapy for particular head and neck cancers. Such indications are formulation- and jurisdiction-dependent and do not imply that hydroxyurea is a standard treatment for all cancers of those sites.
Adverse effects and clinical monitoring
The principal toxicity is bone-marrow suppression. This may cause neutropenia, reduced platelet counts, or anemia. These effects are often reversible after treatment interruption or dose reduction. Clinical monitoring commonly includes a complete blood count and assessment of renal function.
An increase in mean corpuscular volume, the average size of red blood cells, is common. This drug-related macrocytosis does not by itself establish a nutritional deficiency.
Other adverse effects include gastrointestinal symptoms, mouth ulcers, skin and nail pigmentation changes, and cutaneous ulcers, particularly leg ulcers during prolonged treatment. Severe skin reactions and pulmonary toxicity have also been reported.
Hydroxyurea can damage genetic material, and prescribing information includes warnings concerning malignancy. Secondary leukemia and skin cancer have been reported during long-term treatment, particularly in people with myeloproliferative disorders. Attributing leukemia risk to the drug alone is difficult because these underlying disorders can themselves progress to leukemia and some patients have received other cytotoxic treatments. Long-term studies in sickle cell disease have not established a clear treatment-related increase in leukemia, but surveillance remains important.
Hydroxyurea can cause fetal harm based on its mechanism and animal findings. Human pregnancy data remain limited. The drug passes into breast milk, and reduced sperm production has been reported. These reproductive issues are addressed in product labeling and specialist clinical care.
Historical development and research use
Hydroxyurea was first synthesized in the nineteenth century, long before its medical applications were recognized. Its anticancer activity was investigated during the twentieth century. Subsequent recognition that it could increase fetal hemoglobin led to clinical studies in sickle cell disease and its emergence as a major long-term treatment.
Outside clinical medicine, hydroxyurea is used experimentally to slow DNA replication and induce replication stress. It is a laboratory tool for investigating DNA repair, cell-cycle checkpoints, and cellular responses to interrupted DNA synthesis.